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Abstract     
The short chain fatty acid receptor FFA2 is 
able to stimulate signalling via both Gi- and 
Gq/G11-promoted pathways. These pathways 
are believed to control distinct physiological 
endpoints but FFA2 receptor ligands 
appropriate to test this hypothesis have been 
lacking. Herein, we characterize AZ1729, a 
novel FFA2 regulator that acts as a direct 
allosteric agonist and as a positive allosteric 
modulator, increasing the activity of the 
endogenously produced short chain fatty acid 
propionate in Gi-mediated pathways, but not 
at those transduced by Gq/G11. Using AZ1729 
in combination with direct inhibitors of Gi and 
Gq/G11 family G proteins demonstrated that 
although both arms contribute to propionate-
mediated regulation of phospho-ERK1/2 MAP 
kinase signalling in FFA2-expressing 293 
cells, the Gq/G11-mediated pathway is 
predominant. We extend these studies by 
employing AZ1729 to dissect physiological 
FFA2 signalling pathways. The capacity of 
AZ1729 to act at FFA2 receptors to inhibit -
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adrenoceptor agonist-promoted lipolysis in 
primary mouse adipocytes and to promote 
chemotaxis of isolated human neutrophils 
confirmed these as FFA2 processes mediated 
by Gi-signalling, whereas, in concert with 
blockade by the Gq/G11 inhibitor FR900359, 
the inability of AZ1729 to mimic or regulate 
propionate-mediated release of GLP-1 from 
mouse colonic preparations defined this 
physiological response as an end-point 
transduced via activation of Gq/G11. 
 
Introduction 
Short chain fatty acids (SCFAs) are 
carboxylic acids containing 1 to 6 carbons. 
These are produced in the body predominantly 
by the fermentation of non-digestible 
carbohydrates (fibers) through the metabolic 
activity of the gut microbiota, with acetate 
(C2), propionate (C3) and butyrate (C4) being 
the most abundant products (1-2). Until 
recently, the role of SCFAs was believed to be 
confined to providing either a source of 
energy or as intermediate products of more 
complex molecules (1). For example, 
colonocytes utilize C4 as a main energy 
supply, whilst the liver can source C2 as a 
substrate for the synthesis of cholesterol or 
longer chain fatty acids and C3 as a precursor 
for gluconeogenesis (2). However, with the 
discovery and de-orphanization of a pair of G 
protein-coupled receptors (GPCRs) responsive 
to SCFAs, FFA2 and FFA3 (previously 
designated GPR43 and GPR41 respectively) 
(3), it became clear that the SCFAs also act as 
signalling molecules (4-6). The SCFA 
receptors are mainly expressed in tissues 
involved in metabolic regulation, in particular 
white adipose tissue (WAT), intestinal 
enteroendocrine cells and pancreatic beta cells 
(7) and in immune cells (8). Hence, a role for 
the SCFA receptors, in particular FFA2, in 
controlling energy homeostasis, and 
potentially in the regulation of metabolic 
disorders, has been proposed (9-11).  
Despite the increasing interest 
surrounding SCFA receptors, a general 
paucity of selective ligands has rendered the 
study and understanding of their patho-
physiological functions extremely challenging 
(7, 12). For example, although there is a rank 
order of selectivity of endogenous SCFAs for 
the receptors (13), with C2 being more potent 
at human FFA2 than at FFA3, this level of 
selectivity, in concert with the general low 
potency of the SCFAs, is insufficient to allow 
their use in defining physiological roles of 
FFA2 over FFA3 without additional studies 
that incorporate receptor knock-down or 
knock-out models (7). Moreover, even this 
poor degree of SCFA ligand selectivity is 
absent in the mouse orthologs of the SCFA 
receptors, where C2 is equipotent in activating 
FFA2 and FFA3 (7, 14). To date only a small 
number of selective synthetic ligands have 
been identified, with ‘compound 1’ (3-benzyl-
4-(cyclopropyl-(4-(2,5-
dichlorophenyl)thiazol-2-yl)amino)-4-
oxobutanoic acid)  and 4-CMTB ((S)-2-(4-
chlorophenyl)-3-methyl-N-(thiazol-2-
yl)butanamide)  being the best characterized 
ligands with agonist activity at FFA2 (7, 12). 
Although ‘compound 1’ is a selective and 
relatively potent orthosteric agonist at both 
human and mouse FFA2 (15), other 
representatives from this chemical series 
display markedly lower potency at murine 
FFA2 (15), limiting their potential for studies 
in murine cells and tissues (7). Equally, 
although 4-CMTB acts as both a direct 
allosteric agonist and also as a positive 
allosteric modulator (PAM) of the action of 
SCFAs at human FFA2 (16-19), and displays 
similar activity at mouse FFA2, the poor 
pharmacokinetic properties of this ligand (17) 
have limited its use within in vivo validation 
studies for FFA2.  
An interesting feature of FFA2 is that, 
unlike the closely related SCFA receptor 
FFA3 which signals only via Gi-family G 
proteins, it is able to initiate signals via both 
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Gi and Gq/G11-mediated pathways (7, 13). 
However, the contribution of these two 
signalling arms to various downstream 
cascades and, indeed, to physiological 
processes remains, in large part, undefined. 
Clearly, mechanistically distinct and potent 
classes of synthetic ligands are required to 
define such questions. To begin to address this 
need, herein, we characterize a novel synthetic 
ligand N-[3-(2-carbamimidamido-4-methyl-
1,3-thiazol-5-yl)phenyl]-4-fluoro benzamide 
(AZ1729). We demonstrate that AZ1729 acts 
as a FFA2 allosteric agonist and PAM by 
selectively activating Gi-signalling but lacks 
the capacity to activate FFA2 Gq/G11-mediated 
signalling pathways. In this way we define 
AZ1729 as a Gi-biased ligand. In conjunction 
with the use of selective inhibitors of the Gi 
and Gq/G11 classes of G proteins, we then 
employ AZ1729 to define the relative 
contribution of these pathways to the 
integration of ERK1/2-MAP kinase activity in 
transfected cells and in natively expressing 
systems, in which we show that both FFA2-
mediated inhibition of lipolysis and promotion 
of neutrophil chemotaxis reflect signalling via 
Gi-family G proteins. By contrast, in murine 
colonic crypts FFA2 signalling to promote 
release of glucagon-like peptide-1 (GLP-1) is 
not modulated by AZ1729 indicating that this 
response proceeds via activation of Gq/G11.  
 
Results 
AZ1729 activates FFA2-dependent Gi-
signalling. In Flp-In
TM
 T-REx
TM
 293 cells 
(21) able to express human (h)FFA2-eYFP 
only upon addition of the antibiotic 
doxycycline, the physiological  FFA2 receptor 
agonist propionate (C3) (Figure 1A) inhibited 
forskolin-stimulated cAMP levels in a 
concentration-dependent manner (pEC50 = 
3.95 ± 0.13) (Figure 1B). AZ1729 (Figure 
1A), which was identified initially as a 
regulator of FFA2 in a high throughput screen 
conducted using an integrative, function 
agnostic, dynamic mass redistribution assay, 
also inhibited forskolin-stimulated cAMP 
levels in these cells and, equally, did so in a 
concentration-dependent manner (pEC50 = 
6.90 ± 0.14) (Figure 1B). AZ1729 was 
somewhat more efficacious in this assay than 
C3 (74.0% ± 3.1 and 61.1% ± 2.8 inhibition of 
forskolin-stimulated cAMP levels, 
respectively) and also more than 500 fold 
more potent (p < 0.01). By contrast, a 
previously described allosteric agonist of this 
receptor 4-CMTB (16, 18) (Figure 1A), 
although also able to inhibit forskolin-
stimulated cAMP levels (pEC50 = 5.88 ± 0.39) 
was clearly a partial agonist (Figure 1B).  
These effects were dependent on the presence 
of hFFA2 as none of C3, AZ1729 and 4-
CMTB affected cAMP levels in these cells 
when expression of the hFFA2 receptor was 
not induced (Figure 1C). As anticipated, this 
effect of each ligand was transduced via 
Pertussis toxin (PTX)-sensitive Gi-family G 
proteins. Treatment of doxycycline-induced 
cells with PTX, to cause ADP-ribosylation of 
the  subunit of members of this G protein 
subgroup, eliminated ligand regulation of 
cAMP levels in each case (Figure 1D). The 
ability of AZ1729 to induce Gi-mediated 
FFA2 signalling was also assessed in 
[
35S]GTPγS binding assays, an endpoint that is 
best suited to, and usually reflects, the 
contribution of Gi-family G proteins (24). In 
membranes prepared from Flp-In
TM
 T-REx
TM
 
293 cells induced to express hFFA2-eYFP, 
AZ1729 was able to produce stimulation of 
[
35S]GTPγS binding with pEC50 7.23 ± 0.20 
(Figure 1E). Again, this compound displayed 
potency that was significantly higher than 
both C3 (pEC50 4.35 ± 0.14, p<0.01) and 4-
CMTB (pEC50 6.50 ± 0.16, p<0.05), although 
in this case without marked differences in 
ligand efficacy (Figure 1E).  
AZ1729 displays Gi-functional bias at 
FFA2. As well as transducing signals via ‘Gi’ 
the FFA2 receptor is appreciated to be able to 
also interact with, and signal via, Gq/11 G 
proteins (4-6). Indeed, in cells induced to 
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express hFFA2-eYFP, C3 produced a large 
increase in inositol monophosphate (IP1) 
accumulation (Figure 2A), with potency 
(pEC50 = 4.19 ± 0.10) akin to that observed in 
the cAMP-regulation experiments. Whilst 4-
CMTB also produced a partial effect in this 
assay (pEC50 = 5.60 ± 0.11), AZ1729 was 
completely inactive at concentrations up to the 
highest (30 M) that could be tested (Figure 
2A). These observations indicated that 
AZ1729 might be a ‘Gi-biased’ agonist at 
hFFA2. To assess this hypothesis we also 
explored ligand regulation of phospho-
ERK1/2, production of which can be induced 
by both Gi- and Gq/11-mediated signalling. C3 
produced a robust increase of phospho-
ERK1/2 levels (Figure 2B) with potency 
(pEC50 = 3.93 ± 0.13) similar to those 
displayed in both Gi- and Gq/11-dependent 
assays. Interestingly, the effect of C3 on the 
phosphorylation of ERK1/2 was partially 
inhibited by pre-treatment of the cells with 
PTX and greatly reduced by the Gq/G11 
inhibitor FR900359 (22) (Figure 2B), 
suggesting that although C3 mediates 
phospho-ERK1/2 accumulation via both G 
protein classes it is mainly through Gq/G11. In 
the same assay, AZ1729 was only a very weak 
partial agonist at this end point (Figures 2C, 
2D) and also displayed more modest potency 
(pEC50 = 5.66 ± 0.21). Interestingly, the effect 
of AZ1729 on phospho-ERK1/2 accumulation 
was completely abolished in hFFA2 cells pre-
treated with PTX, but unaffected by treatment 
with FR900359 (Figures 2C, 2D). The effects 
of both C3 and AZ1729 were completely 
abrogated upon pre-treatment of cells with 
both PTX and FR900359 (Figures 2B, 2C and 
2D). Together, these data indicate that 
AZ1729 behaves as a biased agonist at 
hFFA2; preferentially activating Gi but being 
unable to engage with Gq/G11 signalling.  
AZ1729 does not interact with the 
orthosteric binding site of FFA2. Synthetic 
agonists at FFA2 that share the same 
orthosteric binding site as C3, and the other 
endogenously produced SCFAs, all contain a 
carboxylate group and this is integral to their 
agonist function (14-15, 28-29). AZ1729 does 
not, and neither does it contain a bioisostere 
that might substitute for the carboxylate 
(Figure 1A). We examined, therefore, if 
AZ1729 acted as an orthosteric agonist. This 
was assessed in two distinct ways. Firstly, we 
examined whether the Gi-mediated agonism of 
AZ1729 was preserved in orthosteric binding 
site mutants of hFFA2. Two arginine residues, 
Arg180 and Arg255 (Ballesteros and 
Weinstein residue location numbers 5.39 and 
7.35, respectively) act to co-ordinate the 
carboxylate moiety of FFA2 orthosteric 
agonists (28). Mutation of either of these 
residues to Ala was able to eliminate the 
ability of C3 to inhibit forskolin-stimulated 
cAMP production (Figure 3A) but did not 
affect substantially the function of AZ1729 
(Figure 3B). Moreover, as described 
previously (18), this was also the case for the 
allosteric agonist 4-CMTB (Figure 3C). 
These data indicate that neither AZ1729 nor 4-
CMTB interact with the arginine residues that 
are the core of the FFA2 orthosteric binding 
pocket (28) and are, therefore, allosteric 
agonists. Secondly, we performed sets of 
radioligand binding experiments. 
[
3
H]GLPG0974 was recently reported as an 
orthosteric radiolabelled antagonist of hFFA2 
(23). In membranes from Flp-In
TM
 T-REx
TM
 
293 cells induced to express hFFA2, 
[
3
H]GLPG0974 bound with high affinity (Kd 
= 7.5 nM) (23) and this was fully outcompeted 
by increasing concentrations of C3 (pKi = 2.78 
± 0.11) (Figure 4A). This was also the case 
when using the previously described hFFA2 
receptor synthetic orthosteric agonist 
‘compound 1’ (15) (Figure 1A) (pKi = 6.58 ± 
0.09) (Figure 4A). However, AZ1729 was 
unable to compete fully with [
3
H]GLPG0974 
for binding to the receptor (Figure 4A), 
demonstrating that AZ1729 does not share an 
overlapping binding site with the radiolabelled 
antagonist. It did, however, produce 
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maximally 16.7 ± 4.4 % reduction in specific 
binding of this radioligand with apparent pKi 
= 6.77 ± 0.50 (Figure 4A). 4-CMTB was also 
poor in capacity to compete with 
[
3
H]GLPG0974, maximally preventing only 
10.9 ± 6.8% of the specific binding of this 
ligand with apparent pKi estimated as 6.64 ± 
1.29 (Figure 4A).  
AZ1729 interacts with a FFA2 
allosteric binding site. The unaltered 
functional effect of AZ1729 at orthosteric 
binding site mutants of hFFA2, and also the 
inability of this compound to fully displace 
[
3
H]GLPG0974, raised the possibility that 
AZ1729 might interact with an allosteric 
binding site on hFFA2. To test this hypothesis 
we performed a three-way radioligand binding 
equilibrium experiment (25). In particular, we 
assessed the ability of 4-CMTB and AZ1729 
to modulate the inhibition of [
3
H]GLPG0974 
binding by the endogenous orthosteric agonist, 
C3. Increasing concentrations of 4-CMTB 
produced a leftward shift of the C3 
concentration-response curve, indicating that 
4-CMTB increases the affinity of C3 to inhibit 
[
3
H]GLPG0974 binding (Figure 4B). Similar 
results were obtained with AZ1729, although 
this compound, in addition to a leftward shift 
of the C3 concentration-response curve, 
produced a downward shift (Figure 4C) as 
anticipated from the modest but detectable 
capacity of AZ1729 to directly modulate 
binding of [
3
H]GLPG0974. Using an extended 
allosteric ternary complex model equation 
(ATCM) (see Methods), we quantified the 
affinity co-operativity factor of 4-CMTB and 
AZ1729 versus [
3H]GLPG0974 (α) and C3 
(α’). This showed that 4-CMTB did not have a 
significant co-operativity effect towards 
[
3H]GLPG0974 binding (α = 0.93, i.e. close to 
unity), whilst AZ1729 displayed a weak 
negative co-operativity effect (α = 0.67). In 
contrast, both 4-CMTB and AZ1729 displayed 
positive co-operativity for C3 binding (α’ = 
4.45 ± 1.16 and 4.27 ± 1.17, respectively). 
From the same equation it was possible to 
calculate the affinity of these synthetic 
compounds for hFFA2 (pKB = 6.52 ± 0.17 for 
4-CMTB and 6.84 ± 0.11 for AZ1729). 
Together, these data indicate that AZ1729, as 
for 4-CMTB, binds to a FFA2 allosteric 
binding site. 
AZ1729 is a functional positive allosteric 
modulator in FFA2-mediated Gi-signalling. 
Having established that AZ1729 displays 
positive co-operativity towards the binding of 
C3 to hFFA2, we investigated whether this 
property would also be observed in functional 
assays. 4-CMTB has been reported to act as 
both a direct agonist of the FFA2 receptor and 
also as an effective PAM of the activity of C3 
(16, 18). This was confirmed in cAMP assays 
in cells induced to express hFFA2 where, as 
well as acting directly as a partial agonist, 4-
CMTB also increased, in a concentration-
dependent fashion, the observed potency of 
C3 (Figure 5A). Application of allosteric 
parameter fitting models allowed estimation of 
the affinity (pKB) of 4-CMTB as 5.68 ± 0.17 
and with the ligand displaying strong positive 
net co-operativity ( = 28.35). In the same 
assay AZ1729 displayed very strong positive 
net co-operativity versus C3, with  = 85.22. 
Since AZ1729 effects on affinity of C3 were 
modest (i.e. ’= 4.27 ± 1.17) the functional 
co-operativity of AZ1729 observed here in the 
C3 cAMP response can be largely attributed to 
enhanced efficacy of C3 in the presence of 
AZ1729. Estimated affinity of AZ1729 for the 
receptor was 6.75 ± 0.12 (Figure 5B), similar 
to the value obtained from the radioligand 
binding experiments.  
These experiments also demonstrated 
that in addition to AZ1729 showing positive 
functional co-operativity in the C3 cAMP 
response this ligand also showed intrinsic 
agonist activity, confirming the data in Figure 
1B that AZ1729 acts as a full agonist (Figure 
5B). Since we are able to estimate the affinity 
of AZ1729 and 4-CMTB from the binding 
experiments (Figure 4A) the agonist activity 
of both of these allosteric modulators can be 
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analysed by fitting the cAMP concentration 
response curves (Figure 1B and Figure 5B) 
to the operational model to generate a measure 
of the transduction efficacy (). Using this 
approach AZ1729 had a  = 5.77 ± 1.22 
compared to a  value of 1.62 ± 1.22 for 4-
CMTB, indicating that AZ1729 drives 
stronger coupling of FFA2 to the cAMP 
signalling pathway than the PAM-agonist 4-
CMTB.  
AZ1729 is a functional negative 
allosteric modulator in hFFA2-mediated 
Gq/G11 signalling. Although lacking direct 
agonism, we next assessed whether AZ1729 
also displayed positive co-operativity in the 
Gq/G11-dependent, IP1 accumulation assay. 
First, we assayed 4-CMTB, which has already 
been reported as a PAM in other Gq/G11-
dependent assays (18). Herein 4-CMTB acted 
as an agonistic PAM of C3 with  = 13.88 
and estimated affinity (pKB) = 5.47 ± 0.20 
(Figure 5C). Surprisingly, in the same assay 
AZ1729 acted instead as an 
insurmountable/allosteric antagonist, as it was 
able to reduce C3 maximal efficacy in a 
concentration-dependent manner, with no 
significant changes in C3 affinity (Figure 
5D). Estimated affinity for AZ1729 in this 
assay was 6.12 ± 0.12 (Figure 5D). 
The ability of AZ1729 to act as a PAM 
in Gi-coupled FFA2 assays but as an 
insurmountable/allosteric antagonist in 
Gq/G11-mediated FFA2 endpoints was further 
assessed in the phospho-ERK1/2 assay. As 
noted earlier (Figure 2B), at FFA2 C3 causes 
accumulation of phospho-ERK1/2 mainly 
through activation of Gq/G11. Increasing 
concentrations of AZ1729, as well as 
displaying weak partial agonism, were able to 
induce a negative effect on C3 maximal 
efficacy (Figure 6A). In order to understand 
the contribution of FFA2-mediated Gi versus 
Gq/G11-signalling, cells were pre-treated with 
PTX or FR900359. After pre-treatment with 
PTX to ablate Gi-mediated signalling and 
allow detection only of Gq/G11-mediated 
signals, AZ1729 retained its ability to induce a 
decrease in the maximal efficacy of the C3 
concentration-response curve, but lost its own 
intrinsic partial agonism (Figure 6B). By 
contrast, in FR900359-pretreated cells, and 
therefore examining only Gi-mediated links to 
this endpoint, AZ1729 did not show any 
negative effect on the C3 concentration-
response curve, but it rather behaved as an 
agonistic PAM, causing an increase in affinity 
of C3 and displaying intrinsic partial agonism 
(Figures 6C, 6D).  Again these data confirm 
the functional bias effect of AZ1729 at 
hFFA2, behaving as an agonistic PAM in Gi-
mediated signalling but as a negative 
allosteric/insurmountable antagonist in 
Gq/G11-mediated signalling. 
AZ1729 displays probe-dependence at 
hFFA2. A common feature of allosteric 
modulators is that they may display ‘probe-
dependence’, i.e. that the characteristics of the 
allosteric modulation can vary with the 
identity of the orthosteric agonist examined 
(30-32). Because ‘compound 1’, the most 
potent orthosteric FFA2 agonist yet described 
(15), is both substantially larger, and 
chemically distinct, from the endogenous 
agonists, we next assessed whether the 
differential effects of AZ1729 in pathways 
mediated by distinct G protein subtypes were 
preserved when using ‘compound 1’. To test 
this, increasing concentrations of AZ1729 
were assayed together with ‘compound 1’ in 
both cAMP and IP1 assays. As with C3, 
AZ1729 was able to increase, in a 
concentration-dependent manner, the observed 
potency of ‘compound 1’ to regulate 
forskolin-induced cAMP accumulation 
(Figure 7A). Application of allosteric 
parameter fitting models resulted in an 
apparent pKB value of 8.39 ± 0.11 and with 
the ligands displaying positive net co-
operativity,  = 12.09. The high affinity 
value obtained in this experiment prompted us 
to assess whether AZ1729 would display a 
similar value also in a three-way radioligand 
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binding experiment in the presence of 
‘compound 1’. AZ1729 was able to strongly, 
and in a concentration-dependent manner, 
induce a leftward shift of the ability of 
‘compound 1’ to compete with 
[
3
H]GLPG0974 for binding, with a maximum 
100 fold increase in ‘compound 1’ affinity in 
the presence of 10 M AZ1729 (Figure 7B). 
Application of the ATCM equation resulted in 
’ = 47.29 ± 0.12 and pKB = 6.51 ± 0.13, 
defining that AZ1729 shows a higher co-
operativity value towards ‘compound 1’ than 
towards C3. We next tested the effect of 
AZ1729 in the Gq/G11-dependent IP1 assay. 
AZ1729 also caused a decrease in the 
maximal efficacy of ‘compound 1’ (Figure 
7C). Together, these results suggest that 
AZ1729, at least for ‘compound 1’, preserves 
its bias effect at FFA2. However, AZ1729 
does display some probe-dependency, having 
a higher co-operativity factor for ‘compound 
1’ than for C3. 
AZ1729 displays FFA2 species 
ortholog-dependent effects. Murine models 
often represent appropriate systems to test 
potential physiological effects of compounds. 
Mouse adipocytes reportedly express FFA2, 
and activation of this receptor has been 
demonstrated to inhibit lipolysis (33-34). 
However, differences in ligand function 
between FFA2 species orthologs have been 
reported (14) and these might limit 
translational interpretation of outcomes in 
such models. As such AZ1729 was next 
assessed in both Gi- and Gq/G11-dependent 
assays in Flp-In
TM
 T-REx
TM
 293 cells that 
were able to express mouse (m)FFA2-eYFP. 
In the cAMP assay, AZ1729 acted as an 
agonist with an efficacy similar to that 
displayed by C3 and with potency of 6.16 ± 
0.12, significantly higher than C3 (p < 0.01) 
(Figure 8A). Again, in the IP1 assay AZ1729 
did not show any direct effect (Figure 8B), 
confirming the bias behavior of this 
compound also at the mouse ortholog of 
FFA2. 
We then moved to test whether the 
allosteric effects of AZ1729 were also 
retained at mFFA2. In cAMP accumulation 
experiments, co-addition of AZ1729 with C3 
resulted in a concentration-dependent increase 
of C3 potency, suggesting that AZ1729 also 
acted as an agonistic PAM at mFFA2 (Figure 
8C). Application of the allosteric model 
equation resulted in an estimated pKB value of 
7.17 ± 0.11 and a net co-operativity factor αβ 
= 13.49. In IP1 accumulation assays AZ1729, 
although displaying no direct effect, was in 
this case able to induce a small increase in the 
potency of the C3 concentration-response 
curve (Figure 8D) with a net co-operativity 
factor αβ = 20.01 and an estimated pKB value 
of 4.95 ± 0.29. Together these data suggest 
that, as for hFFA2, AZ11729 acts as allosteric 
agonist in Gi-coupled end points. However, by 
contrast, the observed antagonism in Gq/G11-
coupled assays at hFFA2 was absent in 
mFFA2. 
AZ1729 induces inhibition of 
isoproterenol-induced lipolysis in mouse 
adipocytes. Having established that AZ1729 is 
Gi-biased we wanted to use this ligand to 
define the physiological signalling pathways 
employed by FFA2 in cells endogenously 
expressing FFA2. As previously stated, 
primary mouse adipocytes express FFA2, and 
activation of this receptor with SCFAs has 
been shown to inhibit lipolysis via a 
mechanism that is mainly Gi-mediated (33-
34). Initially, we tested the expression levels 
of mFFA2 at different stages of differentiation 
in such primary cultures. Differentiation was 
monitored by measuring Ppar, Cebpa and 
Fabp4 mRNA expression levels (Figure 9A). 
In parallel, mFFA2 mRNA levels increased 
with adipocyte differentiation, with 
significantly higher levels at days 6 and 8 of 
the differentiation protocol (Figure 9A). By 
contrast, mRNA corresponding to the closely 
related SCFA receptor FFA3 was not detected 
in these primary murine adipocytes at any 
stage of differentiation.  We then tested the 
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ability of the β-adrenoceptor agonist, 
isoproterenol, to induce lipolysis in these 
cells, with the effect being measured by 
quantification of glycerol release. 
Isoproterenol induced a concentration-
dependent release of glycerol, with pEC50 = 
8.49 ± 0.18 (Figure 9B), similar to that 
reported previously (35). C3 decreased 
isoproterenol-induced glycerol release (pEC50 
= 3.07 ± 0.18) (Figure 9C), also as reported 
previously (34). Similarly, AZ1729 was able 
to produce concentration-dependent (pEC50 = 
5.03 ± 0.44) inhibition of the lipolytic effect 
of isoproterenol (Figure 9C). To define 
whether these effects of both C3 and AZ1729 
were Gi-mediated, primary mouse adipocytes 
were pre-treated with PTX. The effects of 
both C3 and AZ1729 were completely 
abolished when Gi protein activity was 
blocked by PTX pre-treatment (Figure 9D).  
AZ1729 induces migration of human 
neutrophils. The presence of FFA2 has been 
reported in cells of the innate immune system, 
where its expression is particularly marked in 
neutrophils (36-38). In these cells, FFA2 plays 
a role in chemotaxis, with a mechanism that 
seems to be PTX-sensitive, at least in mouse-
derived neutrophils (39). We therefore 
assayed the effect of AZ1729 in human 
neutrophils. First we assessed that the isolated 
cells were positive for CD15, a marker for 
neutrophils. Results show that 98.8% of cells 
were indeed positive for this marker (Figure 
10A). Next we tested whether the isolated 
human neutrophils were able to migrate 
towards the well-known chemoattractant, N-
formyl-methionyl-leucyl-phenylalanine 
(fMLP). Results show that human neutrophils 
were able to migrate towards a concentration-
gradient of fMLP (Figure 10B), producing a 
standard ‘bell-shaped’ response (40) with 
maximal migration induced by 10 nM fMLP. 
Both C3 and AZ1729 were also significantly 
able to induce neutrophil migration at 10 mM 
and 3-10 M, respectively, although to a 
lesser extent than 10 nM fMLP (Figure 10C). 
Because in the in vitro experiments AZ1729 
behaved as an allosteric agonist in Gi-
dependent assays, we assessed the effect of 
AZ1729 on C3-mediated neutrophil migration. 
Neutrophil migration induced by 1 mM C3 
significantly increased in the presence of 1 
M AZ1729, a concentration of the allosteric 
regulator that was unable to promote 
significant neutrophil migration when added 
alone (Figure 10D), indicating that AZ1729 
can potentiate the effect of C3 on neutrophil 
migration.  
AZ1729 does not regulate FFA2-
mediated release of GLP-1 from mouse 
colonic crypts. Production of colonic crypts 
from wild type mice allowed demonstration 
that C3 increased release of GLP-1, and did so 
in a concentration-dependent fashion (Figure 
11A). This ability of C3 was unaffected by 
pre-treatment with PTX but completely 
blocked by addition of FR900359 (Figure 
11B and 11C), indicating this to be a Gq/G11-
mediated effect. As anticipated, C3 did not 
mediate GLP-1 secretion in preparations 
derived from Ffar2 knock-out animals (Figure 
11D). Consistent with this being a Gq/G11-
mediated pathway and the very limited effect 
of AZ1729 observed on Gq/G11-mediated 
signalling in cells heterologously transfected 
to express mouse FFA2, at concentrations of 1 
µM, AZ1729 did not affect GLP-1 release in 
mouse colonic crypts (Figure 11E). Similarly, 
AZ1729 did not affect C3-mediated GLP-1 
release (Figure 11F). 
 
Discussion 
Ligand bias, that is the ability of a 
compound to selectively promote transduction 
of information from a receptor via a subset of 
the panoply of signalling pathways the 
receptor can engage with, compared to the 
effects produced at the same pathways by a 
reference compound, is now well established 
and widely discussed (41-43). Initially, studies 
on ligand bias focused primarily on proof-of-
concept and were frequently limited to 
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experiments performed using receptors 
expressed in heterologous cell systems. 
However, experience derived from such 
studies has facilitated the translation of these 
ideas to native systems, to the extent that 
clinical trials on biased ligands for a number 
of receptors have been performed and more 
are ongoing (44-46). These are designed to 
deliver new medicines with high efficacy but 
with a significant reduction in side-effects that 
reflect engagement with signalling pathways 
that are contra-indicated in effective 
treatment. In many cases assessment of bias at 
GPCRs has focussed largely on separation of 
the effectiveness of ligands to regulate signals 
that reflect either ‘canonical’ G protein-
dependent or ‘non-canonical’, non-G protein-
dependent effects. The non-G protein-
dependent effects are routinely assessed as 
interactions with arrestins, in part because a 
variety of assays allow easy measurement of 
such interactions but, also in part, because it is 
clear that arrestins allow both kinetically- and 
spatially-distinct signals to be developed after 
ligand engagement with a GPCR (47-48). 
Despite this, it is clear that many GPCRs can 
interact with and signal via members of more 
than one of the four broad families of 
heterotrimeric G proteins. As such, ligand bias 
can also be generated between activation of 
such G protein families. In early days such 
studies centred on the ability of ligands to 
selectively activate Gs vs Gi-mediated 
pathways but in recent times the development 
of a wide range of G protein subtype selective 
biosensors has resulted in more global 
assessments of ligand and receptor bias across 
the G protein family (49-52). 
 Initial deorphanization studies on 
FFA2 (then designated GPR43) highlighted 
the capacity of this receptor to regulate both 
Gi and Gq/G11-mediated signals when 
stimulated with SCFAs (5) and subsequent 
work has confirmed this dual signalling 
capacity. Moreover, until now this has also 
been the case for synthetic activators of FFA2, 
whether binding to the orthosteric (15) or to 
an allosteric (16, 18-19) site.  
AZ1729 was identified initially in a 
high throughput screen designed to discover 
regulators of FFA2. As this compound is 
devoid of a carboxylic acid moiety, which 
appears to be essential for orthosteric agonist 
actions at FFA2 (23), it was anticipated to act 
as an allosteric regulator. This was confirmed 
in that AZ1729 maintained agonist function 
and potency at orthosteric binding site mutants 
of FFA2, was unable to effectively 
outcompete specific binding of the FFA2 
orthosteric antagonist [
3
H]GLPG0974 (23) 
and acted as a PAM of the functional potency 
of the SCFA C3 in cAMP assays. Each of 
these is incompatible with AZ1729 acting as 
an orthosteric ligand. In recent times, applying 
modifications of the ‘operational model’ of 
ligand function has allowed assessment of the 
binding affinity of allosteric ligands to GPCRs 
and the degree of co-operativity produced 
upon co-binding of an allosteric and 
orthosteric ligand (25). Although AZ1729 was 
unable to compete directly with 
[
3
H]GLPG0974 for binding to FFA2, it did 
produce a marked alteration in the observed 
affinity of C3 to do so.  Analysis of this effect 
using the ACTM generated  pKB = 6.84 ± 0.11 
for AZ1729, and a very similar value for 
binding affinity of this ligand was obtained via 
analysis of the effect of AZ1729 on C3-
mediated inhibition of forskolin-stimulated 
cAMP levels.   
As initial studies on the activity of 
AZ1729 focussed on assays that were PTX-
sensitive and, therefore, mediated via ‘Gi’-
family G proteins, we were surprised that in 
the Gq/G11-dependent IP1 assay AZ1729 was 
inactive as an agonist. Therefore, we turned to 
assessment of ERK1/2 phosphorylation. In 
Flp-In
TM
 T-REx
TM
 293 cells induced to 
express hFFA2, C3 produced a large, 
concentration-dependent increase in 
phosphorylation of these proteins, as reported 
previously (15, 28). This clearly reflected an 
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integration of ‘Gi’ and Gq/G11-initiated signals 
because a combination of pre-treatment with 
PTX and the Gq/G11-inhibitor FR900359 was 
required to eliminate the effect of C3. By 
contrast, AZ1729 displayed very poor efficacy 
in this assay. Moreover, the modest effect of 
AZ1729 was unaffected by FR900359, 
indicating that it was not transduced via 
Gq/G11, but blocked by PTX treatment. 
However, AZ1729 still binds to hFFA2 in this 
context and, indeed, acted rather as an 
insurmountable/allosteric antagonist of the 
function of C3 in the Gq/G11-mediated IP1 
assay. 
Hence, our studies demonstrate that 
AZ1729 is an allosteric modulator that binds 
to a topographically distinct site from that of 
the endogenous orthosteric ligand (C3) in a 
manner that selectively enhances the coupling 
of FFA2 to Gi-signalling pathways through a 
mechanism that primarily involves an increase 
in the efficacy of the orthosteric ligand (i.e  
value) with only a modest contribution made 
through an increase in the affinity of the 
orthosteric ligand (i.e.  value). Remarkably, 
the PAM activity of AZ1729 is selective to Gi-
signalling since AZ1729 acts in the opposite 
direction in the context of Gq/11 signalling – 
namely decreasing the coupling efficacy of the 
orthosteric ligand to this signalling pathway. 
The selective nature of the PAM activity of 
AZ1729 is not only useful to probe the 
physiologically relevant signalling pathways 
downstream of FFA2 activation (as described 
below) but also establishes an important 
general principle that it is possible to generate 
PAMs to GPCRs that selectively enhance 
receptor coupling to one signalling pathway 
over another through a mechanism that is 
largely independent of the modulation of 
orthosteric agonist affinity but rather centred 
on the modulation of agonist efficacy.    
Although the capacity of FFA2 to 
couple to various G proteins has been 
catalogued extensively in cell systems 
expressing the receptor in a heterologous 
manner, there remains a lack of information 
regarding FFA2-mediated signal transduction 
in cells endogenously expressing this receptor 
(7) and the contribution of different G proteins 
to initiation of these signals. It has been 
suggested that biased ligands, by 
preferentially activating specific receptor 
signalling pathways, can be valuable tools to 
assess the mechanistic basis of biological 
processes (42). Our experiments highlight this 
capability of biased ligands and give further 
information regarding the molecular 
mechanisms underpinning FFA2-mediated 
physiology by exploiting the unique 
pharmacology of AZ1729. In this regard, we 
assessed actions of AZ1729 in primary cells 
expressing FFA2 endogenously. The selective 
‘Gi’-mediated agonist effects of AZ1729 
allowed prediction that because neutrophil 
chemotaxis towards SCFAs is a PTX-sensitive 
FFA2 effect (37, 39), then AZ1729 should be 
functional in such assays. Indeed it was: 
although much less efficacious than a 
maximally effective concentration of the well 
characterized neutrophil chemotactic agent 
fMLP, AZ1729 was as effective as C3 and 
functioned in a concentration-dependent 
manner. Moreover, it also acted as a PAM of 
the potency of C3. A concentration of AZ1729 
that was ineffective in isolation enhanced the 
effect of a sub-maximal concentration of C3.  
The molecular basis of FFA2-mediated anti-
lipolytic effects was also assessed in murine 
adipocytes. As anticipated from previous 
work, following ex vivo ‘differentiation’ of 
adipocytes produced from mouse epididymal 
fat, a process which acted to substantially 
upregulate levels of FFA2 mRNA, AZ1729 
was as effective, and much more potent, than 
C3 in inhibiting isoproterenol-stimulated 
lipolysis and release of glycerol (33-34). 
These data confirm the ability of FFA2 to 
reduce lipolysis in a Gi-dependent manner, 
further demonstrating the utility of AZ1729 to 
identify FFA2-mediated effects that rely on Gi 
-mediated signalling in physiologically 
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relevant cells expressing the receptor 
endogenously.  
In contrast to this was the lack of 
capacity of AZ1729 to modulate incretin 
secretion. C3 is able to stimulate an incretin 
effect in mouse colonic tissue and cultures 
(53-54), promoting secretion of significantly 
enhanced levels of GLP-1 as confirmed 
herein. This was clearly a Gq/G11-mediated 
effect as it was blocked by treatment with 
FR900359 and not reduced by treatment of the 
cells with PTX. Moreover, as anticipated for a 
defined Gq/G11-mediated endpoint, AZ1729 
was unable to recapitulate the incretin effect 
of C3, further confirming that FFA2 
modulates GLP-1 secretion via a Gq/11 
mechanism in mouse colonic crypts. It is 
interesting to note in this regard that a 
compound BTI-A-404, recently described as a 
selective and potent competitive inverse 
agonist of human FFA2/GPR43 (55) has been 
reported to promote GLP-1 secretion in a 
human cell line. Whether there is divergence 
between mouse and human FFA2 signal 
transduction at this endpoint thus requires 
further investigation.  Together, these data 
highlight the ability of FFA2 to engage with 
different signalling pathways in physiological 
contexts as well as in transfected cell systems 
and shows that FFA2 pharmacology is tissue 
dependent. Thus, AZ1729 could be helpful in 
unravelling the signalling pathways behind the 
physiological roles of FFA2 and, potentially, 
its contribution to pathological states. 
Overall, we provide detailed characterization 
of a novel FFA2 receptor allosteric ligand, 
AZ1729, which shows the unique property of 
being biased to generate functional effects 
only at PTX-sensitive effects of FFA2. In 
conjunction with the use of selective G protein 
pathway inhibitors this ligand can be used to 
specify G protein selection and will provide 
novel insights to the potential value of bias in 
G protein-signalling in areas of FFA2 biology 
of potential clinical relevance. 
 
Materials and Methods 
Chemistry. All solvents and reagents 
were purchased from commercial suppliers 
and used without further purification. 
Analytical HPLC/MS was conducted on a 
Waters Zevo QTof or Waters LCT Premiere 
mass spectrometer using an Acquity PDA 
(Waters) UV detector monitoring either at (a) 
210 nm with an Acquity BEH C18 column 
(2.1x100 mm, 1.7 µm, 0.7 mL/min flow rate), 
using a gradient of 2 % v/v acetonitrile in H2O 
(ammonium carbonate buffer pH 10) to 98 % 
v/v acetonitrile in H2O or (b) 230 nm with an 
Acquity HSS C18 column (2.1x100 mm, 1.8 
µm, 0.7 mL/min flow rate), using a gradient of 
2 % v/v acetonitrile  in H2O (ammonium 
formate buffer pH 3) to 98 % v/v acetonitrile 
in H2O. Preparative HPLC was conducted 
using a Waters Fraction Lynx Purification 
System using either (i) Xbridge Prep C18 5 
µm OBD 19 mm x 150 mm columns. The 
mobile phase used was varying gradients of 
acetonitrile and 0.1 M HCO2H buffer; flow 
rate 30 mL/min. 
1
H NMR spectra were 
generated on a Varian 300 MHz, Varian 400 
MHz, Varian 500 MHz or Varian 600 MHz 
instrument. Chemical shifts (δ) are given in 
parts per million (ppm), with the residual 
solvent signal used as a reference. NMR 
abbreviations are used as follows: br = broad, 
s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet. 
Synthesis of 1-[5-(3-aminophenyl)-4-
methyl-1,3-thiazol-2-yl]guanidine. 1-[5-(3-
aminophenyl)-4-methyl-1,3-thiazol-2-
yl]guanidine was synthesized according to the 
procedure described in PCT Int. Appl. (2007), 
WO 2007120096 A1 20071025 (20). 
Synthesis of N-[3-(2-
carbamimidamido-4-methyl-1,3-thiazol-5-
yl)phenyl]-4-fluorobenzamide. 1-[5-(3-
aminophenyl)-4-methyl-1,3-thiazol-2-
yl]guanidine (64 mg, 0.26 mmol) was 
dissolved in tetrahydrofuran (1.5 mL) and 
triethylamine (0.036 mL, 0.26 mmol) was 
added followed by 4-fluorobenzoyl chloride 
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(41.0 mg, 0.26 mmol). The solution was 
stirred at room temp for 3 hours. The crude 
was concentrated and dissolved in DMSO, 
filtered and purified by HPLC, using a 
gradient of 5-95 % acetonitrile  in 0.1 M 
HCO2H as mobile phase, to yield 62 mg (64.9 
%) of N-[3-(2-carbamimidamido-4-methyl-
1,3-thiazol-5-yl)phenyl]-4-fluorobenzamide.  
LC-MS m/z (ES+): 370.1 
1
H NMR (DMSO-d6): δ 2.31 (s, 3H), 6.88 (br 
s, 3H), 7.11 (d, 1H), 7.32 – 7.42 (m, 3H), 7.69 
(d, 1H), 7.79 – 7.83 (m, 1H), 7.97 – 8.08 (m, 
2H), 10.32 (s, 1H). 
Cell culture. All transformed cell lines 
used in these experiments were derived from 
Flp-In
TM
 T-REx
TM
 293 cells (21) and were 
designed to express the desired receptor, either 
human or mouse FFA2, on demand following 
induction with the antibiotic doxycycline (14-
15). In all cases, the receptor construct 
expressed was fused in-frame to enhanced 
yellow fluorescent protein (eYFP) at its C 
terminal. The cells were maintained in 
Dulbecco’s modified Eagle’s medium 
(DMEM) without sodium pyruvate, 
supplemented with 10% (v/v) foetal bovine 
serum and penicillin/streptomycin mixture 
(Sigma-Aldrich; Poole, Dorset, UK) in a 
humidified atmosphere containing 5% CO2. 
To induce receptor expression, cells were 
incubated overnight with 100 ng.ml
-1
 
doxycycline. Pre-treatments with PTX and/or 
FR900359 (22) were performed by incubating 
cells overnight with 100 ng.ml
-1
 PTX and/or 
for 30 min with 100 nM FR900359. 
cAMP assays. Were performed using a 
homogeneous time-resolved fluorescence 
(HTRF
®
) cAMP dynamic kit (CisBio 
Bioassays; CisBio, Codolet, France). Cells 
were plated at 2000 cells/well in low-volume 
384-well plates, and inhibition of 1 µM 
forskolin-stimulated cAMP production was 
assessed following a 30 min co-incubation 
with test compounds. Outputs were measured 
by using a PHERAstar FS plate reader (BMG 
Labtech, Aylesbury, UK). 
IP1 accumulation assays. Were 
performed using a HTRF
®
 IP1 dynamic kit 
(CisBio Bioassays). Cells were plated at 7500 
cells/well in low-volume 384-well plates and 
incubated for 2 h at 37ºC with test 
compounds. Reactions were stopped 
according to the manufacturer's instructions 
and signal measured by using a PHERAstar 
FS plate reader.  
Extracellular signal-regulated kinase 
(ERK) 1/2 phosphorylation assays. Were 
performed using a HTRF
®
 phospho-ERK1/2 
kit (CisBio Bioassays). Briefly, cells were 
plated at 70,000 cells/well in 96-well plates 
and then allowed to adhere for 3–6 h. 
Doxycycline was then added (100 ng.ml
-1
) to 
induce expression of the receptor of interest, 
and cells were maintained in culture 
overnight. Prior to the assay, cells were serum 
starved for 4-6h. After this, cells were treated 
with test compounds and incubated for 5 min 
at 37ºC, lysis buffer was then added and cells 
were incubated on a shaker for 30min. 
Phospho-ERK1/2 reagents were added 
according to the manufacturer's instructions 
and signal measured using a PHERAstar FS 
plate reader. 
Membrane preparation.  Membranes 
were generated from Flp-In
TM
 T-REx
TM
 293 
cells either non-treated or treated with 
doxycycline (100 ng.ml
-1
) to induce 
expression of FFA2. Briefly, cells were 
removed from flasks by scraping and 
centrifuged at 3000 rpm for 5 min at 4ºC. 
Pellets were resuspended in TE buffer (75 mM 
Tris–HCl; 5 mM  EDTA; pH 7.4) containing  
a protease inhibitor cocktail (Roche, West 
Sussex, UK) and homogenized with a 5 mL 
hand-held homogenizer. This material was 
centrifuged at 1500 rpm for 7 min at 4ºC and 
the supernatant was further centrifuged at 
50000 rpm for 45 min at 4ºC. The resulting 
pellet was resuspended in TE buffer and 
protein content was assessed using a BCA 
protein assay kit (Pierce, Fisher Scientific, 
Loughborough, UK).  
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Radioligand competition and three-
way binding assays. Assays were carried out 
with 7.5 nM [
3
H]GLPG0974 ([
3
H]4-[[1-
(benzo[b]thiophene-3-carbonyl)-2-
methylazetidine-2-carbonyl]-(3-
chlorobenzyl)amino]butyric acid) (23), Tris 
binding buffer (50 mM Tris-HCl, 100 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.4) 
and indicated concentrations of test 
compounds in a  total assay volume of 200 L 
in glass tubes. Binding was initiated by the 
addition of membranes (5 µg protein per 
well). All assays were performed at 25°C for 2 
h before termination by the addition of ice-
cold Phosphate Buffered Saline (PBS) and 
vacuum filtration through GF/C glass filters 
using a 24-well Brandel cell harvester (Alpha 
Biotech, Glasgow, UK). Each reaction well 
was washed six times with 1.2 mL aliquots of 
Tris-binding buffer. The filters were allowed 
to dry for 2-3 h and then placed in 3 mL of 
Ultima Gold™ XR (Perkin Elmer, 
Beaconsfield, UK). Radioactivity was 
quantified by liquid scintillation spectrometry. 
Specific binding was defined as the difference 
between binding detected in the presence and 
absence of 10 µM unlabelled GLPG0974.  
[
35S]GTPγS incorporation assay. 
Assays (24) were carried out with reactions 
containing 5 μg of cell membrane proteins 
pre-incubated for 15 min at 25°C in assay 
buffer (50 mM Tris-HCl, pH 7.4; 10 mM 
MgCl2; 100 mM NaCl; 1 mM EDTA; 1 μM 
GDP; and 0.1% fatty acid-free bovine serum 
albumin) with the indicated concentrations of 
ligands in a total assay volume of 500 L in 
glass tubes. Reactions were initiated by 
addition of [
35S]GTPγS (50 nCi per tube), and 
terminated after 1 h incubation at 25°C by 
rapid filtration through GF/C glass filters 
using a 24-well Brandel cell harvester (Alpha 
Biotech, Glasgow, UK). Unbound radioligand 
was removed from the filters by three washes 
with ice-cold wash buffer (50 mM Tris-HCl, 
pH 7.4, and 10 mM MgCl2), and [
35
S]GTPγS 
binding was determined by liquid scintillation 
spectrometry. Non-specific binding was 
measured in the presence of 100 µM GTPγS.  
Data analysis and curve fitting. All 
data presented represent mean ± SEM of at 
least three independent experiments. Data 
analysis and curve fitting were carried out 
using the GraphPad Prism software package 
v5.0b. Concentration-response data were fit to 
three-parameter sigmoidal concentration-
response curves. Three-way binding 
experiments were fitted using the Extended 
Allosteric Ternary Complex operational 
model equation 1 described previously (25): 
 
 
 
 
where Y is the measured response, whilst KI, 
KA and KB represent the equilibrium 
dissociation constants of the radioligand 
[
3
H]GLPG0974, unlabelled orthosteric ligand 
(C3 and compound 1) and allosteric modulator 
(AZ1729 and 4-CMTB), respectively, with [I], 
[A] and [B] indicating their concentrations. α 
is the measure of the affinity cooperativity 
factor between the allosteric modulator and 
the radioligand [
3H]GLPG0974, whilst α’ is 
the measure of the affinity cooperativity factor 
between the allosteric modulator and 
unlabelled orthosteric ligand. 
For functional studies (cAMP and IP1 
accumulation assays), allosteric parameters 
were calculated by using the operational 
model equation 2 described previously (18): 
 
 
 
 
where E is the measured response, and A and 
B represent the orthosteric and allosteric 
ligands, respectively. In this equation, Em is 
the maximal system response, α is a measure 
of the allosteric cooperativity on ligand-
binding affinity, and β is an empirical measure 
of the allosteric effect on efficacy. KA and KB 
are measures of the binding affinities of the 
Y =  100([I]+(KA])  
[I]+((K
A 
K
B
)/(α[B]+K
B
))((1+([I]
S
/K
I
)+([B]/K
B
)+(α’[I]
S
[B])/(K
I
K
B
)) 
Equation 1. 
E =  Em(τA[A](KB+αβ[B])+τB[B]KA)
n
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  Equation 2. 
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orthosteric and allosteric ligands, respectively. 
The value n represents the slope factor of the 
transduction function, whereas the abilities of 
the orthosteric and allosteric ligands to 
directly activate the receptor are incorporated 
through the values τA and τB. To fit 
experimental data to this equation, in all cases 
the system maximum (Em), slope (n) and KA 
functions were constrained, allowing for 
estimations of α, β, τA, τB and KB. To fit the 
data presented in Figures 5D and 7C, the α 
value was constrained to 1 to fit data for 
AZ1729 that did not perturb the potency of the 
allosteric ligand, whilst τB was set to a value 
of effectively 0 to fit data for AZ1729 that did 
not produce any direct effect on its own. 
Animals. C57BL/6J mice purchased 
from Charles River (Margate, Kent, UK) were 
used to derive primary mouse adipocytes. 
FFAR2-/- mice were generated by Deltagen 
(26) and backcrossed for 4 generations onto 
C57BL6/J at AstraZeneca, Mölndal. Animals 
were cared for in accordance with national 
guidelines on animal experimentation.  
Derivation of primary mouse 
adipocytes. Epididymal fat was collected from 
male mice, finely minced and digested in 
HEPES buffer (100 mM HEPES, 120 mM 
NaCl, 4.8 mM KCl, 127 mM CaCl2, 4.5 mM 
glucose, 1.5% albumin, pH 7.4) containing 
0.2% collagenase II (Sigma-Aldrich) for 30 
min at 37ºC with rotation. After this time, 
digested material was filtered through a cell 
strainer (70 µm) and incubated for 15 min on 
ice. Sedimented stromal-vascular fraction was 
then collected and centrifuged at 1500 RCF 
for 10 min. Cells were resuspended in DMEM 
medium (DMEM, 10% foetal bovine serum, 4 
mM glutamine, 10 mM HEPES, 10 µg/ml 
insulin, 25 µg/ml sodium ascorbate) to 1000 
cells/µl and seeded into 96 well plates, final 
volume 150 µl. Cells were maintained at 37ºC, 
5% CO2. Medium was replaced the day after 
cell isolation with DMEM medium containing 
10 µM rosiglitazone. Medium was 
subsequently replaced every 2-3 days until the 
day of the experiment. 
Lipolysis assay. Test compounds were 
prepared at the indicated concentrations in 
Hanks Balanced Salt Solution (HBSS) 
containing 25 mM glucose and 2% fatty acid-
free bovine albumin serum. Differentiated 
primary mouse adipocytes were washed three 
times with HBSS prior to the addition of test 
compounds. Cells were then incubated at 
37°C for 2 h and, after this time, 50 µl of cell 
supernatants was transferred to a 96-well 
plate. Glycerol concentration in the 
supernatants was measured by the addition of 
50 µl/well free glycerol reagent (Sigma-
Aldrich). Plates were then incubated at 37°C 
for 5 min before absorbance at 540 nm was 
measured using a Pherastar FS microplate 
reader. 
Human neutrophils: Isolation and 
migration assay. Neutrophils were isolated 
from human whole blood using the 
MACSxpress® Neutrophil Isolation Kit 
according to the manufacturer protocol 
(Miltenyi Biotec, Bergisch Gladbach, 
Germany). Isolated neutrophils were 
resuspended in RPMI 1640 containing 0.5% 
fatty acid-free bovine serum albumin. Test 
compounds were prepared at the indicated 
concentrations in the same buffer and added at 
the bottom of a 24-well plate (Sigma-Aldrich). 
Inserts were then mounted to the plate and 
neutrophils were added (5000 cells/µl). Cells 
were incubated at 37°C for 1.5 h and migrated 
cells were then collected and counted using a 
haemocytometer.  
Flow cytometry. Isolated human 
neutrophils were incubated for 30 min with 
CD15-FITC or isotype-FITC antibodies 
(Biolegend, London, UK). Cells were 
analysed with BD FACSCalibur
TM
 platform 
(BD Biosciences, Oxford Science Park, UK) 
and analyses were performed with FlowJo 
software (TreeStar, Eugene, OR). 
Quantitative PCR. Total RNA from 
mouse adipocytes was prepared by cell lysis 
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and purification using miRNeasy micro kits 
(Qiagen). The miScript Reverse Transcription 
Kit (Qiagen) was used for cDNA preparation. 
TaqMan Gene Expression Assays (Applied 
Biosystems) were used for determination of 
gene expression. The expression of TATA 
binding protein (TBP) was used as control and 
data were analyzed using an ABI7900HT 
machine with SDS 2.2 software. Data are 
presented as RQ values (2
−ΔΔCT
) with 
expression relative to endogenous control and 
control sample at day 1 of differentiation. 
Mouse colonic preparations and GLP-
1 release assays. Murine colonic crypt 
cultures were prepared as previously described 
(27). Briefly, the muscle layer from the colon 
and rectum was removed.  The remaining 
tissue was washed in PBS, chopped and 
digested with 0.4 mg.ml
-1
 collagenase XI 
(Sigma) at 37°C into cell clusters resembling 
crypts. Crypts were seeded onto 24-well plates 
coated with Matrigel (Corning), and incubated 
overnight at 37°C and 5 % CO2. Experiments 
were performed after 1 day in vitro, except for 
the PTX experiments, which were performed 
after 2 days. Crypts were incubated with 100 
nM FR900359 for 30 min or 200 ng.ml
-1
 PTX 
for 16-18 h prior to addition of test ligands. 
Test ligands were added in 138 buffer (mM: 
HEPES 10, NaCl 138, KCl 4.5, NaHCO3 4.2,  
NaH2PO4 1.2, CaCl2 2.6, MgCl2 1.2) 
containing 500 Kallikrein Inhibitor Unit.ml
-1
 
aprotinin, 10 µM amastatin, and 0.1 mM 
diprotin A to inhibit breakdown of GLP-1, and 
incubated for 2 h at 37°C and 5 % CO2. 
Supernatants were removed, and cells lysed 
using lysis buffer (Tris HCl 50mM, NaCl, 
150mM, C24H39NaO4 ·H2O, 0.5%, Igepal CA-
630, 1%) containing Complete EDTA-free 
protease inhibitor cocktail. Secretion 
supernatants were centrifuged at 4°C and 
8,000 RCF, and lysates at 4°C and 21,130 
RCF to pellet cell debris. Active GLP-1 
concentrations were determined by ELISA 
(Millipore). Secretion is expressed as GLP-1 
released over the 2 h incubation period as a 
percentage of the total crypt GLP-1 content.  
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Footnotes 
Non-standard abbreviations. ATCM, allosteric ternary complex model; DMEM, Dulbecco’s 
modified Eagle’s medium; eYFP, enhanced yellow fluorescent protein; fMLP, N-formyl-
methionyl-leucyl-phenylalanine; GLP-1, glucagon-like peptide-1;  GPCR, G protein-coupled 
receptor; HBSS, Hank’s Balanced Salt Solution; HTRF, homogeneous time-resolved 
fluorescence; PAM, positive allosteric modulator; PBS, Phosphate Buffered Saline; PTX, 
pertussis toxin; SCFA, short chain fatty acid, WAT, white adipose tissue. 
Chemical names. AZ1729, N-[3-(2-carbamimidamido-4-methyl-1,3-thiazol-5-yl)phenyl]-4-
fluoro benzamide; 4-CMTB, (S)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide; 
‘compound 1’,  3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-
oxobutanoic acid; GLPG0974, (4-[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-
carbonyl]-(3-chlorobenzyl)amino]butyric acid). 
 
Figure Legends 
Figure 1. AZ1729 is a potent activator of Gi-dependent FFA2-signalling. Chemical structures 
of C3, AZ1729, ‘compound 1’ and 4-CMTB are shown (A). The effect of C3, 4-CMTB and 
AZ1729 on forskolin-induced stimulation of cAMP production in Flp-In
TM
 T-REx
TM
 293 cells 
that had been induced to express hFFA2 (B) or such cells that were pre-treated with PTX (D) is 
shown. Compound effects require hFFA2 as without induction of the receptor no responses were 
observed (C). The effect of C3, 4-CMTB and AZ1729 on [
35S]GTPγS incorporation in 
membranes of hFFA2 expressing cells  (E). Data are expressed as percentage inhibition of 
forskolin-stimulated cAMP production (B-D) or percent stimulation of [
35S]GTPγS binding (E). 
Results represent means ± SEM (n = 9-12). 
 
Figure 2. AZ1729 is a Gi-biased regulator of FFA2. The effect of C3, 4-CMTB and AZ1729 
on IP1 accumulation assay in Flp-In
TM
 T-REx
TM
 293 cells, induced to express hFFA2, is  shown 
(A). The effect of C3 (B) and AZ1729 (C) on ERK1/2 phosphorylation in Flp-In
TM
 T-REx
TM
 293 
cells induced to express hFFA2 that had been pre-treated or not with PTX and/or FR900359.  
Data are expressed as the percentage of IP1 accumulation taking as 100 % the maximal effect of 
C3 (A), or ERK1/2 phosphorylation signal ratio between 665 and 620 nm multiplied by a factor 
of 10000 (B-C). (D) Displays the same data as (C) but presents the information % of the 
maximal effect of AZ1729 in untreated FFA2 expressing cells (control).  Results represent 
means ± SEM (n = 6-8). 
 
Figure 3. AZ1729 signalling via FFA2 is not affected by mutations in the orthosteric 
binding pocket. The effect of C3 (A), AZ1729 (B) and 4-CMTB (C) on forskolin-induced 
stimulation of cAMP production in Flp-In
TM
 T-REx
TM
 293 cells that had been induced to express 
wild type, Arg180Ala or  Arg255Ala mutants for hFFA2. Data are expressed as the percentage 
inhibition of cAMP production. Results represent the means ± SEM (n = 6).  
 
Figure 4. AZ1729 is a positive allosteric regulator of C3 affinity at FFA2. The ability of 
varying concentrations  of C3, AZ1729, 4-CMTB and ‘compound 1’ to compete with 
[
3
H]GLPG0974 in equilibrium competition binding experiments in membranes of Flp-In
TM
 T-
REx
TM
 293 cells induced to express hFFA2  is shown (A). The effect of increasing 
concentrations of 4-CMTB (B) or AZ1729 (C) on the ability of C3 to compete with 
 at G
lasgow
 U
niversity Library on A
ugust 31, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 Ligand bias at Free Fatty Acid 2 receptor 
21 
 
[
3
H]GLPG0974 binding in membranes expressing hFFA2 is displayed. Data are expressed as the 
percentage of specific [
3
H]GLPG0974 binding. Results represent the means ± SEM (n = 6-10). 
 
Figure 5. AZ1729 is a positive allosteric modulator of hFFA2-mediated Gi-signalling. The 
effect of increasing concentrations of 4-CMTB (A, C) or AZ1729 (B, D) on C3 regulation of 
forkolin-induced cAMP production (A, B) or IP1 accumulation (C, D). Data are expressed as the 
percentage inhibition of cAMP production (A, B) or IP1 accumulation taking as 100% the 
maximal response of C3 (C, D). Results represent the means ± SEM (n = 6-10). 
 
Figure 6. AZ1729 displays differential FFA2-mediated Gi and Gq/11 signalling effects: 
Studies on ERK1/2 phosphorylation. The effect of increasing concentrations of AZ1729 on C3 
concentration-response curves on ERK1/2 phosphorylation assays in hFFA2 expressing cells that 
were untreated (A) or had been pre-treated with PTX (B) or with FR900359 (C). (D) Displays 
the same data as (C) but presents the information as % of the maximal effect of C3 in FR900359-
pre-treated hFFA2 expressing cells. Results represent means ± SEM (n = 6). 
 
Figure 7. AZ1729 is a potent allosteric modulator of ‘compound 1’ at hFFA2. The effect of 
increasing concentrations of AZ1729 on ‘compound 1’ concentration-response curves in 
forskolin-induced cAMP production (A), competition binding studies using  [
3
H]GLPG0974 (B) 
and IP1 accumulation (C) assays is shown. Results represent means ± SEM (n = 6-10). 
 
Figure 8. AZ1729 also displays functional bias at mouse FFA2. The effect of C3 or AZ1729 
in Flp-In
TM
 T-REx
TM
 293 cells induced to express mFFA2 on forskolin-induced cAMP 
production (A) or IP1 accumulation (B) assays is shown. The effect of increasing concentrations 
of AZ1729 on C3 concentration-response curves in forskolin-induced cAMP production (C) or 
IP1 accumulation (D) assays is also displayed. Results represent means ± SEM (n =6-8). 
 
Figure 9. AZ1729 inhibits lipolysis in primary mouse adipocytes. Gene expression profiles of 
Ffar2, Ppar, Cebpa and Fabp4 in primary mouse adipocytes at day 1, 2, 3, 6 and 8 of 
differentiation (A). The effect of varying concentrations of isoproterenol on glycerol production 
in differentiated primary mouse adipocytes is displayed (B). The effect of increasing 
concentrations of C3 and AZ1729 on 10 nM isoproterenol-induced glycerol release in 
differentiated primary mouse adipocytes that were untreated (C) and or had been pre-treated with 
PTX (D) is shown. Data are shown as expression of target genes relative to samples at day 1 of 
differentiation (A) or as percentage of glycerol release taking as 100% the maximal effect of 10 
nM isoproterenol (B-D).  Results represent means ± SEM (n = 4-8). ** p < 0.01; # p < 0.05; ### 
p < 0.001; +++ p < 0.001; $$$ p < 0.001 one-way ANOVA followed by Dunnett’s post hoc test 
(A). *** P < 0.001 two-way ANOVA followed by Bonferroni post hoc test (D). 
 
Figure 10. AZ1729 induces human neutrophil migration. Human neutrophils were labelled 
with isotype-FITC (A, left panel) or CD15-FITC (A, right panel) antibody and analysed by 
FACS. The effect of increasing concentration of fMLP on human neutrophil migration (B). The 
effect of 10 nM fMLP, 10 mM C3 and increasing concentrations of AZ1729 on human 
neutrophil migration (C). The effect of single treatment or co-incubation of 1 mM C3 and 1 µM 
AZ1729 on human neutrophil migration is compared to the effect of 10 nM fMLP (D). Data are 
expressed as the number of migrated neutrophils (B) or as the percentage of migrated neutrophils 
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taking as 100 % the response to 10 nM fMLP (C, D). Results represent the mean ± SEM (n = 4-
7). Forward Light Scatter indicates cell size. Statistical analyses were performed by comparing 
the migratory response of each sample to vehicle-treated neutrophils (B, C). * p < 0.05; ** p < 
0.01; *** p < 0.001 one-way ANOVA followed by Dunnett’s post hoc test (B,C). *** P < 0.001; 
$$$
 p < 0.001 one-way ANOVA followed by Bonferroni post hoc test (D).  
 
Figure 11. AZ1729 does not regulate FFA2-mediated release of GLP-1 from mouse colonic 
crypts. The effect of increasing concentrations of C3 on GLP-1 secretion in mouse colonic 
crypts (A). The effect of 1 mM C3 on GLP-1 secretion in mouse colonic crypts that had or had 
not been pretreated with PTX (B) or FR900359 (C). The effect of 1 mM C3 on GLP-1 secretion 
in mouse colonic crypts derived from heterozygous (+/-) or knock-out (-/-) mice for Ffar2 (D). 
The effect of AZ1729 alone (E) or in combination with 1 mM C3 (F) on GLP-1 secretion in 
mouse colonic crypts. * p < 0.05; ** p < 0.01 one-way ANOVA followed by Dunnett’s post hoc 
test (A and F). * p < 0.05 unpaired t test (B, C, D and E). 
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